S&P 500   3,320.79 (-0.27%)
DOW   29,196.24 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,483.03 (+0.24%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
GE   11.65 (-1.35%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
BAC   34.25 (-1.35%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.24 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,483.03 (+0.24%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
GE   11.65 (-1.35%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
BAC   34.25 (-1.35%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.24 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,483.03 (+0.24%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
GE   11.65 (-1.35%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
BAC   34.25 (-1.35%)
GILD   62.63 (-0.56%)
S&P 500   3,320.79 (-0.27%)
DOW   29,196.24 (-0.52%)
QQQ   223.28 (-0.04%)
AAPL   317.23 (-0.47%)
MSFT   166.50 (-0.36%)
GOOGL   1,483.03 (+0.24%)
AMZN   1,892.00 (+1.46%)
CGC   24.17 (-2.89%)
NVDA   247.94 (-0.54%)
BABA   222.01 (-2.38%)
MU   58.97 (+2.27%)
GE   11.65 (-1.35%)
TSLA   547.20 (+7.19%)
AMD   51.05 (+0.24%)
T   38.52 (+0.34%)
ACB   2.00 (-6.11%)
F   9.21 (+0.55%)
NFLX   338.11 (-0.46%)
PRI   126.37 (-1.60%)
BAC   34.25 (-1.35%)
GILD   62.63 (-0.56%)
Log in
(Ad)
In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

NASDAQ:OBLN - Obalon Therapeutics Stock Price, Forecast & News

$2.02
+0.12 (+6.32 %)
(As of 01/21/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.91
Now: $2.02▼
$2.14
50-Day Range
$1.75
MA: $1.85▼
$1.93
52-Week Range
$1.52
Now: $2.02▼
$23.30
Volume1.14 million shs
Average Volume215,112 shs
Market Capitalization$15.53 million
P/E RatioN/A
Dividend YieldN/A
Beta-4.67
Obalon Therapeutics, Inc, a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Obalon balloon system designed to provide weight loss in obese patients. Obalon Therapeutics, Inc was founded in 2008 and is headquartered in Carlsbad, California.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBLN
Previous Symbol
CUSIPN/A
CIK1427570
Webhttp://www.obalon.com/
Phone844-362-2566

Debt

Debt-to-Equity Ratio0.03
Current Ratio5.72
Quick Ratio5.20

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.10 million
Price / Sales1.71
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.57 per share
Price / Book0.36

Profitability

EPS (Most Recent Fiscal Year)($19.60)
Net Income$-37,380,000.00
Net Margins-607.48%
Return on Equity-228.96%
Return on Assets-103.25%

Miscellaneous

Employees100
Outstanding Shares7,690,000
Market Cap$15.53 million
Next Earnings Date2/28/2020 (Estimated)
OptionableOptionable

Receive OBLN News and Ratings via Email

Sign-up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:OBLN Rates by TradingView

Obalon Therapeutics (NASDAQ:OBLN) Frequently Asked Questions

What is Obalon Therapeutics' stock symbol?

Obalon Therapeutics trades on the NASDAQ under the ticker symbol "OBLN."

When did Obalon Therapeutics' stock split? How did Obalon Therapeutics' stock split work?

Obalon Therapeutics's stock reverse split on Thursday, July 25th 2019. The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2019. An investor that had 100 shares of Obalon Therapeutics stock prior to the reverse split would have 10 shares after the split.

How were Obalon Therapeutics' earnings last quarter?

Obalon Therapeutics Inc (NASDAQ:OBLN) posted its quarterly earnings results on Friday, November, 8th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($3.50) by $2.89. The firm earned $0.33 million during the quarter, compared to the consensus estimate of $2.20 million. Obalon Therapeutics had a negative return on equity of 228.96% and a negative net margin of 607.48%. View Obalon Therapeutics' Earnings History.

When is Obalon Therapeutics' next earnings date?

Obalon Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Obalon Therapeutics.

What price target have analysts set for OBLN?

4 equities research analysts have issued 1 year target prices for Obalon Therapeutics' shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Obalon Therapeutics' stock price to reach $20.63 in the next twelve months. This suggests a possible upside of 941.7% from the stock's current price. View Analyst Price Targets for Obalon Therapeutics.

What is the consensus analysts' recommendation for Obalon Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obalon Therapeutics in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Obalon Therapeutics.

Has Obalon Therapeutics been receiving favorable news coverage?

News headlines about OBLN stock have been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Obalon Therapeutics earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Obalon Therapeutics.

Who are some of Obalon Therapeutics' key competitors?

What other stocks do shareholders of Obalon Therapeutics own?

Who are Obalon Therapeutics' key executives?

Obalon Therapeutics' management team includes the folowing people:
  • Mr. Andrew P. Rasdal, Exec. Chairman (Age 61)
  • Dr. Kelly Huang Ph.D., CEO, Pres & Director (Age 50)
  • Mr. William John Plovanic CFA, CFO & Sec. (Age 50)
  • Mr. Mark C. Brister, Chief Technology Officer (Age 57)
  • Ms. Daina Schmidt, VP of Marketing

When did Obalon Therapeutics IPO?

(OBLN) raised $75 million in an initial public offering on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Obalon Therapeutics?

Shares of OBLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obalon Therapeutics' stock price today?

One share of OBLN stock can currently be purchased for approximately $1.98.

How big of a company is Obalon Therapeutics?

Obalon Therapeutics has a market capitalization of $15.23 million and generates $9.10 million in revenue each year. The company earns $-37,380,000.00 in net income (profit) each year or ($19.60) on an earnings per share basis. Obalon Therapeutics employs 100 workers across the globe.View Additional Information About Obalon Therapeutics.

What is Obalon Therapeutics' official website?

The official website for Obalon Therapeutics is http://www.obalon.com/.

How can I contact Obalon Therapeutics?

Obalon Therapeutics' mailing address is 5421 Avenida Encinas Suite F, Carlsbad CA, 92008. The company can be reached via phone at 844-362-2566 or via email at [email protected]


MarketBeat Community Rating for Obalon Therapeutics (NASDAQ OBLN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  222 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  468
MarketBeat's community ratings are surveys of what our community members think about Obalon Therapeutics and other stocks. Vote "Outperform" if you believe OBLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel